Abstract:Background Hepatocellular carcinoma (HCC) is one of the most lethal human tumors with extensive intratumor heterogeneity (ITH). Serine protease 3 (PRSS3) is an indispensable member of the trypsin family and has been implicated in the pathogenesis of several malignancies, including HCC. However, the paradoxical effects of PRSS3 on carcinogenesis due to an unclear molecular basis impede the utilization of its biomarker potential. We hereby explored the contribution of PRSS3 transcripts to tumor functional heterogeneity by systematically dissecting the expression of four known splice variants of PRSS3 ( PRSS3-SVs, V1~V4 ) and their functional relevance to HCC. Methods The expression and DNA methylation of PRSS3 transcripts and their associated clinical relevance in HCC were analyzed using several publicly available datasets and validated using qPCR-based assays. Functional experiments were performed in gain- and loss-of-function cell models, in which PRSS3 transcript constructs were separately transfected after deleting PRSS3 expression by CRISPR/Cas9 editing. Results PRSS3 was aberrantly differentially expressed toward bipolarity from very low ( PRSS3 Low ) to very high ( PRSS3 High ) expression across HCC cell lines and tissues. This was attributable to the disruption of PRSS3-SVs , in which PRSS3-V2 and/or PRSS3-V1 were dominant transcripts leading to PRSS3 expression, whereas PRSS3-V3 and -V4 were rarely or minimally expressed. The expression of PRSS3-V2 or -V1 was inversely associated with site-specific CpG methylation at the PRSS3 promoter region that distinguished HCC cells and tissues phenotypically between hypermethylated low-expression (m PRSS3-SV Low ) and hypomethylated high-expression (um PRSS3-SV High ) groups. PRSS3-SVs displayed distinct functions from oncogenic PRSS3-V2 to tumor-suppressive PRSS3-V1 , -V3 or PRSS3-V4 in HCC cells. Clinically, aberrant expression of PRSS3-SVs was translated into divergent relevance in patients with HCC, in which significant epigenetic downregulation of PRSS3-V2 was seen in early HCC and was associated with favorable patient outcome. Conclusions These results provide the first evidence for the transcriptional and functional characterization of PRSS3 transcripts in HCC. Aberrant expression of divergent PRSS3-SVs disrupted by site-specific CpG methylation may integrate the effects of oncogenic PRSS3-V2 and tumor-suppressive PRSS3-V1 , resulting in the molecular diversity and functional plasticity of PRSS3 in HCC. Dysregulated expression of PRSS3-V2 by site-specific CpG methylation may have potential diagnostic value for patients with early HCC.

Serine protease PRSS56, a novel cancer-testis antigen activated by DNA hypomethylation, promotes colorectal and gastric cancer progression via PI3K/AKT axis

Promoter hypermethylation of GALR1 acts as an early epigenetic susceptibility event in colorectal carcinogenesis

A new high-throughput screening methodology for the discovery of cancer-testis antigen using multi-omics data

Genome-Wide Methylation Profiling of lncRNAs Reveals a Novel Progression-Related and Prognostic Marker for Colorectal Cancer

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

Identification and Expression Analysis of PRM1 as a Novel Candidate Cancer/Testis Gene in Human Colorectal Cancer

Epigenetic Silencing of PRSS3 Provides Growth and Metastasis Advantage for Human Hepatocellular Carcinoma

Downregulation of ZNF365 by Methylation Predicts Poor Prognosis in Patients with Colorectal Cancer by Decreasing Phospho-P53 (ser15) Expression

Epigenetic Silencing of Protocadherin 10 in Colorectal Cancer.

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Methylated Promoters of Genes Encoding Protocadherins As a New Cancer Biomarker Family.

Protocadherin 17 Acts As a Tumour Suppressor Inducing Tumour Cell Apoptosis and Autophagy, and is Frequently Methylated in Gastric and Colorectal Cancers

CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma

PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer

Promoter Demethylation Mediates the Expression of ZNF645, a Novel Cancer/testis Gene

PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

PRMT6 functionally associates with PRMT5 to promote colorectal cancer progression through epigenetically repressing the expression of CDKN2B and CCNG1

Protamine 1 as a secreted colorectal cancer-specific antigen facilitating G1/S phase transition under nutrient stress conditions

Regulation of a PRMT5/NF-κB Axis by Phosphorylation of PRMT5 at Serine 15 in Colorectal Cancer

Serine protease PRSS23 drives gastric cancer by enhancing tumor associated macrophage infiltration via FGF2